

EQUITIES

ON THE MOVE CORPORATE PROFILES

Grant Life Sciences, Inc.

OTC BB: GLIF

64 East Winchester Suite 205 Murray, Utah 84107
Phone: 801-261-8736 • www.grantlifesciences.com

TOP 10 INVESTMENT HIGHLIGHTS

- ☑ Potential to corner the market as the only company with patented blood-based testing products under development for cervical cancer screening.
- ☑ Preliminary testing results show Grant Life Sciences' first-generation blood test, AbREACT™, is easier to use and more cost-effective than currently available testing methods.
- ☑ Enormous and growing market for cervical-cancer screening.
- ☑ Grant plans to market its cervical cancer screening products globally, by itself or through partnerships, with expectations that diagnostic advances will hold far greater appeal over traditional invasive testing methods, which are less technologically efficient and often unsuitable to women in non-western cultures.
- ☑ Grant's first-generation blood test AbREACT™ is advantageous for healthcare professionals, as it utilizes an industry standard Enzyme Linked Immunosorbent Assay (ELISA), a testing format that can be conducted in clinical laboratory settings worldwide, with results in approximately two hours.
- ☑ In April 2006, Grant Life Sciences Inc. entered into a Memo of Understanding (MOU) with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). The proposed deal would include upfront payment of \$250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology. A definitive licensing agreement will be signed following appropriate due diligence and a feasibility test.
- ☑ Grant's second-generation blood test, QuickStrip™, is planned as a point-of-care test that could be administered in the physician's office, or even at home, providing results in 10 to 15 minutes.
- ☑ Grant holds exclusive rights to the AccuDx Corporation's rapid tests for Dengue Fever, HIV-1 and HIV-2, and is revitalizing the marketing, sales, and distribution efforts.
- ☑ Grant's management team and advisory board have extensive experience in the medical technology industry.
- ☑ Additional products in pipeline and in-licensing activity underway.

CORPORATE OVERVIEW

Grant Life Sciences, Inc. (OTC BB: GLIF) is a developmental stage medical technology company. Grant's primary focus is to research, develop, market, and sell diagnostic testing with emphasis on the detection of cervical cancer and cervical

cancer precursors. The company is developing two cervical cancer screening tests. One is AbREACT™, an Enzyme Linked Immunosorbent Assay (ELISA), to be run in clinical laboratories. The second, a rapid test called QuickStrip™, is a point-of-care test that

would be administered in the hospital, physician's office, or at home.

These tests would detect the presence or absence of specific antibodies that are produced only if cancer-causing HPV, human papillomavirus, is present in the body and consequent oncogenic or cancer-promoting changes occur. The company also holds worldwide licenses, acquired from AccuDx Corporation, for diagnostic tests for Dengue Fever, HIV-1, HIV-2, and proprietary colloidal gold reagent, an ingredient used by manufacturers of rapid tests as a detectable label. Grant Life Sciences was organized in 1998 and is based in Los Angeles, California, and Murray, Utah.

MARKET OPPORTUNITY FOR GRANT LIFE SCIENCES CERVICAL CANCER SCREENING PRODUCT

Grant Life Sciences, Inc., seeks to bring accessible, accurate, and rapid testing methods to a market where such diagnostic devices currently do not exist. Invasive cervical cancer affects over 500,000 women worldwide annually and causes approximately 300,000 deaths each year. Cervical cancer is the second highest cause of cancer death among women.

Approximately 60 million Pap tests, screening for cervical abnormalities, are performed annually in the United States, and an additional 60 million Pap tests performed annually in the rest of the world, mainly in Canada, Western Europe and Japan. In the rest of the world, approximately 1.7 billion women do not undergo regular cervical cancer screening tests; contributing factors include a lack of economic resources, as well as socio-cultural and/or religious issues. In some nations, the mortality rate of cervical cancer approaches 100 percent.

CURRENT CERVICAL CANCER SCREENING PRODUCTS / DIAGNOSTICS LIMITATIONS

Traditional and liquid Pap tests, the most prevalent cervical cancer screening method for more than 50 years, have limited predictive values. Nine million colposcopies, an invasive procedure, are performed annually worldwide on patients with abnormal Pap test results, but only 20 percent of those colposcopies reveal cervical cancer or pre-cancerous conditions. False positives and false negative test results are common, and procedures result in high cost.

HPV (Human Papillomavirus) and Cervical Cancer

HPV, a sexually transmitted disease, is a precursor to virtually all cervical cancer. According to the Center for Disease Control, approximately 20 million people are currently infected with HPV. At least 50 percent of sexually active men and women acquire genital HPV infection at some point in their lives. By age 50, at least 80 percent of sexually active women will have acquired genital HPV infection. HPV can be detected with DNA testing; however, out of the approximately 100 types of HPV only between 7 to 15 HPV types cause most cervical cancers. In recent years, DNA-based HPV tests have been introduced as an adjunct to the Pap test. These tests detect the presence of the virus; however, HPV presence alone does not necessarily indicate cancer.

GRANT'S CERVICAL CANCER SCREENING PRODUCTS / DIAGNOSTIC ADVANTAGES:

It is Grant's belief that a sensitive, reliable, non-invasive point-of-care testing for cervical cancer will enhance the prospects for extensive use by women and their healthcare providers worldwide. By analyzing a small amount of the patient's blood, Grant's patented testing methods detect antibodies that appear only when cervical cancer and pre-cancerous conditions are present in the body. Such conditions are evidenced by certain proteins that facilitate cervical cancer development.

■ **AbReact™**, Grant's first-generation blood test, is intended to be an industry-standard for clinical settings. Using standard laboratory equipment, Enzyme Linked Immunosorbent Assay (ELISA), and analytic software, test results for cervical cancer can be completed in approximately two hours.

■ **QuickStrip™**, Grant's second-generation blood test, provides easy-to-read results in approximately 15 minutes and is designed to be administered by a healthcare professional in a doctor's office, hospital, or in the patient's home.

Grant seeks to market its cervical cancer screening tests in major countries such as China, India, Mexico and Canada as well as in the United States. In the United States alone, approximately \$4 billion is spent by women on Pap tests annually.

ADDITIONAL PRODUCTS AND TECHNOLOGY

Grant Life Sciences Owns Exclusive Rights to AccuDx Corporation's Rapid Tests

In 2005, Grant Life Sciences purchased exclusive worldwide rights for rapid diagnostic testing of Dengue Fever, HIV-1 and HIV-2 from the AccuDx Corporation. AccuDx is a biotechnology company based in La Jolla, Calif., founded by Ravi Pottahil, Ph.D., one of the world's leading authorities in the field of HIV/AIDS diagnostics and therapeutics.

Grant Life Sciences, Inc., has already shipped orders of the Dengue Fever and Malaria rapid diagnostic tests to India and is revitalizing AccuDx's distributor networks in overseas markets. Grant's goal is to have a global distributorship network in place, along with the requisite manufacturing capacity, so that it can begin selling its core products, essentially their tests for detecting cervical cancer and its precursors, as soon as the tests are ready for commercialization.

In-Licensing of Technology Sponsored by the U.S. Government Bio Industry Initiative

Grant Life Sciences Inc. has signed a Memorandum of Understanding (MOU) with Dr. Peter Sveshnikov and Dr. Vsevolod Kiselev of the Russian Republic, for the in-licensing of certain technologies that are highly complementary to Grant's' antibody-based test for detecting cervical cancer. Together, when validated, Grant will have two complementary cervical dysplasia or cancer diagnostic tests that will work on blood serum or cervical mucous and cells. A test employing cervical mucous or cells is readily fitting for Western medical venues and has the potential of reducing costs dramatically when compared against those for current HPV DNA-testing. Furthermore, it could significantly reduce expenditures for follow-up referral procedures that turn out to be overwhelmingly negative, with billions of dollars per year in unnecessary medical expenses saved as a consequence.

MANAGEMENT

Stan Yakatan, MBA, Chairman

Dr. Hun Chi-Lin, President, CSO and Director

Donald Rutherford, CFO

This corporate profile is based upon information provided by management of Grant Life Sciences, Inc. The information is not intended to be, and shall not constitute, an offer to sell or solicitation of any offer to buy any security. It is intended for information only, and to increase awareness of Grant Life Sciences, Inc.'s services. Safe Harbor Statement: The statements in this document relating to future product availability, collaboration and partnership, and positive direction are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the aspects anticipated by these forward-looking statements may not, in fact, occur. Factors that could cause or contribute to such differences include, but are not limited to, contractual difficulties, demand for Grant Life Sciences, Inc.'s products, the future market price of Grant Life Sciences, Inc. common stock, and the Company's ability to obtain necessary future financing. EQUITIES Magazine was paid \$7,500 by Grant Life Sciences, Inc. to write and print this profile in the Summer issue of EQUITIES Magazine. Before investing in any security, you are strongly advised to review all public filings of the issuer of such security, which can be found at www.sec.gov, as well as the warnings published by the Securities and Exchange Commission at <http://www.sec.gov/investor.shtml>.